The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer
Abstract
PURPOSE: The development of bone metastases depends on tumor-induced osteoclastic resorption of bone, which may be inhibited by the antiosteolytic bisphosphonate clodronate. Given to patients with primary breast cancer, clodronate might reduce the subsequent incidence of bone metastases. PATIENTS AND METHODS: This double-blind, multicenter trial accrued 1,069 assessable patients with operable breast cancer between 1989 and 1995. All patients received surgery, radiotherapy, chemotherapy, and tamoxifen as required. Patients were randomized to receive oral clodronate 1,600 mg/d or a placebo for 2 years starting within 6 months of primary treatment. The primary end point was relapse in bone, analyzed on an intent-to-treat basis, during the medication period and during the total follow-up period (median follow-up, 2,007 days). Secondary end points were relapse in other sites, mortality, and toxicity. RESULTS: During the total follow-up period, there was a nonsignificant reduction in occurrence of bone metastases (clodronate, n = 63; placebo, n = 80; hazards ratio [HR], 0.77; 95% confidence interval [CI], 0.56 to 1.08; P = .127). During the medication period there was a significant reduction in the occurrence of bone metastases (clodronate, n = 12; placebo, n = 28; HR, 0.44; 95% CI, 0.22 to 0.86; P = .016). The occurrence of nonosseous metastases was similar (clodronate, n = 112; placebo, n = 128; P = .257), but there was a significant reduction in mortality (clodronate, n = 98; placebo, n = 129; P = .047) during the total follow-up period. CONCLUSION: Clodronate, given to patients with primary operable breast cancer, may reduce the occurrence of bone metastases, although this reduction was only significant during this medication period. There was a significant reduction in mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J., Knight, R. D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352401 · Cited by 1,026
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I. J., Solomayer, E.-F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Theriault, R. L., Lipton, A., Hortobagyi, G. N., Leff, R., Glück, S., Stewart, J. F., Costello, S., Kennedy, I., Simeone, J., Seaman, J. J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.846 · Cited by 604
Fleisch, H. (1991) · Drugs · doi:10.2165/00003495-199142060-00003 · Cited by 581
Paterson, A. H., Powles, T. J., Kanis, J. A., McCloskey, E., Hanson, J., & Ashley, S. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.59 · Cited by 557
Self-citationSaarto, T., Blomqvist, C., Virkkunen, P., & Elomaa, I. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.10 · Cited by 341
Mechanisms of bone destruction in the development of skeletal metastases
GALASKO, C. S. B. (1976) · Nature · doi:10.1038/263507a0 · Cited by 272
Clodronate decreases the frequency of skeletal metastases in women with breast cancer
Kanis, J. A., Powles, T., Paterson, A. H. G., McCloskey, E. V., & Ashley, S. (1996) · Bone · doi:10.1016/s8756-3282(96)00285-2 · Cited by 224
Self-citationLong-term controlled trial with diphosphonate in patients with osteolytic bone metastases.
Elomaa, I., Blomqvist, C., Gröhn, P., Porkka, L., Kairento, A.-L., Selander, K., Lamberg-Allardt, C., & Holmström, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92755-1 · Cited by 209
Powles, T. J., Clark, S. A., Easty, D. M., Easty, G. C., & Neville, A. M. (1973) · British Journal of Cancer · doi:10.1038/bjc.1973.154 · Cited by 195
Self-citationPowles, T. J., Ashley, S., Tidy, V. A., Nevantaus, A., McCloskey, E., Kanis, J. A., Paterson, A. H. G., & Rosenqvist, K. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.704 · Cited by 159
Self-citationBisphosphonates as Anticancer Drugs
Mundy, G. R., & Yoneda, T. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390609 · Cited by 126
Cited by
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Bisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
Hillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.017 · Cited by 970
A systematic review of the role of bisphosphonates in metastatic disease
Ross, J., Saunders, Y., Edmonds, P., Patel, S., Wonderling, D., Normand, C., & Broadley, K. (2004) · Health Technology Assessment · doi:10.3310/hta8040 · Cited by 467
Metadata
- Authors
- Powles, T., Paterson, S., Kanis, J. A., McCloskey, E., Ashley, S., Tidy, A., Rosenqvist, K., Smith, I., Ottestad, L., Legault, S., Pajunen, M., Nevantaus, A., Männistö, E., Suovuori, A., Atula, S., Nevalainen, J., & Pylkkänen, L.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-08-01
- Volume
- 20
- Issue
- 15
- Pages
- 3219-3224
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2159100092
- Cited by
- 377
- References
- 12
- FWCI
- 20.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.